Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.53 |
| ▸ | CCR2 | P41597 | 8/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SLC40A1 | Q9NP59 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | OXTR | P30559 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29948966 | 1.00 | TRPV4 (0.53) | TRPV4CCR2ALDH1A1L3MBTL1SLC40A1 | |
| SCHEMBL533050 | 0.84 | TRPV4 (0.50) | TRPV4CCR2ALDH1A1L3MBTL1 | |
| SCHEMBL13343225 | 0.83 | CCR2 (0.51) | TRPV4CCR2ALDH1A1L3MBTL1SLC40A1 | |
| SCHEMBL29009817 | 0.81 | CCR2 (0.50) | TRPV4CCR2ALDH1A1L3MBTL1SLC40A1 | |
| SCHEMBL2774927 | 0.81 | CCR2 (0.50) | CCR2ALDH1A1L3MBTL1SLC40A1 | |
| SCHEMBL12560662 | 0.81 | CCR2 (0.68) | TRPV4CCR2ALDH1A1L3MBTL1SLC40A1 | |
| SCHEMBL29899701 | 0.80 | AKR1B1 (0.46) | TRPV4CCR2ALDH1A1PKMPOLB | |
| SCHEMBL113810 | 0.80 | AKR1B1 (0.46) | TRPV4CCR2ALDH1A1PKMPOLB | |
| Hydrochloric Acid SCHEMBL28031219 | 0.79 | CCR2 (0.49) | TRPV4CCR2ALDH1A1L3MBTL1SLC40A1 | |
| Hydrochloric Acid SCHEMBL7003803 | 0.78 | AKR1B1 (0.45) | TRPV4CCR2ALDH1A1PKMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111689881-B | Synthetic method of azosemide intermediate | 苏州华道生物药业股份有限公司 | 2022-04-01 | — | — | CN | claimed |
| CN-111689881-A | Synthetic method of azosemide intermediate | 苏州华道生物药业股份有限公司 | 2020-09-22 | — | — | CN | claimed |
| US-20260085067-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | BOUNDLESS BIO INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-20250326770-A1 | BENZOTRIAZOLE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-10-23 | — | — | US | disclosed |
| US-20250282724-A1 | BENZOTRIAZOLE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-09-11 | — | — | US | disclosed |
| US-12378260-B2 | Benzotriazole compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-08-05 | — | — | US | disclosed |
| EP-4587437-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | Boundless Bio, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250092064-A1 | BENZOTRIAZOLE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-03-20 | — | — | US | disclosed |
| EP-4509504-A1 | BENZOTRIAZOLE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2025-02-19 | — | — | EP | disclosed |
| CN-119173511-A | Benzotriazole compounds | 第一三共株式会社 | 2024-12-20 | — | — | CN | disclosed |
| CN-119118894-A | TRPV4 receptor ligands | 犹他大学研究基金会 | 2024-12-13 | — | — | CN | disclosed |
| WO-2006029210-A2 | ACYCLIC 1,3-DIAMINES AND USES THEREFOR | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006024390-A1 | HEXAHYDRO-PYRAZINO[1,2-A]PYRIMIDINE-4, 7-DIONE DERIVATIVES SUBSTITUTED WITH AMINO ACIDS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-03-09 | — | — | WO | disclosed |
| EP-1597259-A1 | NITROGEN-SUBSTITUTED HEXAHYDROPYRAZINO 1,2-A]PYRIMIDINE-4,7-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
| WO-2005075424-A1 | NEW PYRIDIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005058826-A1 | NEW 5,6-DIHYDROPYRIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN | ASTRAZENECA AB (SE) | 2005-06-30 | — | — | WO | disclosed |
| US-20050085483-A1 | Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-04-21 | — | — | US | disclosed |
| WO-2004072077-A1 | NITROGEN-SUBSTITUTED HEXAHYDROPYRAZINO[1,2-A]PYRIMIDINE-4,7-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSHLAND GMBH (DE) | 2004-08-26 | — | — | WO | disclosed |
| US-5476846-A | Administering anti-thrombotic and anti-asthmatic agent | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1995-12-19 | — | — | US | disclosed |
| US-5387709-A | Bronchodilator agents, anticoagulants, vasodilation | LIPHA LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1995-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085067-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | RRM1, RRM2B, RRM2 | TRPV4 4334/4885CCR2 473/4885ALDH1A1 998/4885 |
| US-20250092064-A1 | BENZOTRIAZOLE COMPOUND | NFE2L2, BPTF, KEAP1 | TRPV4 2544/4885CCR2 2015/4885ALDH1A1 416/4885 |
| US-12378260-B2 | Benzotriazole compound | NFE2L2, BPTF, KEAP1 | TRPV4 2544/4885CCR2 2015/4885ALDH1A1 416/4885 |
| US-20050085483-A1 | Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments | DPYD, NUDT1, NT5C2 | TRPV4 322/4885CCR2 3416/4885ALDH1A1 458/4885 |
| US-20250326770-A1 | BENZOTRIAZOLE COMPOUND | KEAP1, NFE2L2, TXNRD2 | TRPV4 3953/4885CCR2 2863/4885ALDH1A1 588/4885 |
| US-20250282724-A1 | BENZOTRIAZOLE COMPOUND | NFE2L2, BPTF, KEAP1 | TRPV4 2544/4885CCR2 2015/4885ALDH1A1 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.